Clinical development of an antisense therapy for the treatment of transthyretin-associated polyneuropathy

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Amyloid: Journal of Protein Folding Disorders

• Publication date

  2012-05-24

• Fields of study

  Medicine

• Identifiers
  DOI 10.3109/13506129.2012.673140PMID 22494066
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial.

  2010cited by this paper
• Phase II Trial of OGX-011 in Combination with Docetaxel in Metastatic Breast Cancer

  2009cited by this paper

• RNA Interference Therapeutics for Hereditary Amyloidosis: A Narrative Review of Clinical Trial Outcomes and Future Directions

  2024cites this paper
• S2k-Leitlinie Lebertransplantation der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) und der Deutschen Gesellschaft für Allgemein- und Viszeralchirurgie (DGAV)

  2024cites this paper
• Hepatocyte targeting via the asialoglycoprotein receptor

  2024cites this paper
• Downregulation of SF3B2 protects CNS neurons in models of multiple sclerosis

  2022cites this paper
• Novel approaches to diagnosis and management of hereditary transthyretin amyloidosis

  2022cites this paper
• RNA-based therapeutics for neurological diseases

  2022cites this paper
• Brazilian consensus for diagnosis, management and treatment of hereditary transthyretin amyloidosis with peripheral neuropathy: second edition

  2022cites this paper
• Charge‐Conversion Strategies for Nucleic Acid Delivery

  2021cites this paper
• Disease-Modifying Treatments for Transthyretin Amyloidosis

  2021cites this paper
• Machine learning-derived electrocardiographic algorithm for the detection of cardiac amyloidosis

  2021cites this paper
• Deliver the promise: RNAs as a new class of molecular entities for therapy and vaccination

  2021cites this paper
• DDDT_A_237252 1057..1081

  2020cites this paper
• Review on the Structures and Activities of Transthyretin Amyloidogenesis Inhibitors

  2020cites this paper
• Disease-Modifying Pharmacological Therapies for Transthyretin Cardiac Amyloidosis

  2020cites this paper
• Neuropathy symptom and change: Inotersen treatment of hereditary transthyretin amyloidosis

  2020cites this paper
• Evaluating the Knockdown Activity of MALAT1 ENA Gapmers In Vitro.

  2020cites this paper
• Controlling Protein Expression by Delivery of RNA Therapeutics Using Lipid Nanoparticles

  2019cites this paper
• inotersen: new promise for the treatment of hereditary transthyretin amyloidosis

  2019cites this paper
• Diagnostic and Treatment Approaches Involving Transthyretin in Amyloidogenic Diseases

  2019cites this paper
• Prevalence of Cardiac Amyloidosis in Patients with Carpal Tunnel Syndrome

  2019cites this paper
• Clinical electrophysiology of axonal polyneuropathies.

  2019cites this paper
• Simultaneous Tc-99m PYP/Tl-201 dual-isotope SPECT myocardial imaging in patients with suspected cardiac amyloidosis

  2019cites this paper
• New simple and quick method to analyze serum variant transthyretins: direct MALDI method for the screening of hereditary transthyretin amyloidosis

  2019cites this paper
• Inotersen: new promise for the treatment of hereditary transthyretin amyloidosis

  2019cites this paper
• A new staging system for cardiac transthyretin amyloidosis

  2018cites this paper
• Are we under Diagnosing Cardiac Amyloidosis in the Aged Population

  2018cites this paper
• Diagnosis and management of transthyretin familial amyloid polyneuropathy in Japan: red-flag symptom clusters and treatment algorithm

  2018cites this paper
• Antisense oligonucleotides and other genetic therapies made simple

  2018cites this paper
• Cardiac amyloidosis: An update on pathophysiology, diagnosis, and treatment.

  2018cites this paper
• Spectrum of Restrictive and Infiltrative€Cardiomyopathies

  2018cites this paper
• Recent advances in diagnosis and treatment of cardiac amyloidosis.

  2018cites this paper
• Spectrum of Restrictive and Infiltrative Cardiomyopathies: Part 1 of a 2-Part Series.

  2018cites this paper
• Amyloid seeding of transthyretin by ex vivo cardiac fibrils and its inhibition

  2018cites this paper
• Insights into the pharmaceuticals and mechanisms of neurological orphan diseases: Current Status and future expectations

  2018cites this paper
• Progression of transthyretin (TTR) amyloidosis in donors and recipients after domino liver transplantation—a prospective single‐center cohort study

  2018cites this paper
• Familial Cardiac Amyloidoses

  2018cites this paper
• Precise Medicine of Restrictive Cardiomyopathy

  2018cites this paper
• Advances in the Diagnosis and Treatment of Amyloidosis and Related Disorders

  2018cites this paper
• Clinical Proof of Concept for a Novel Hepatocyte-Targeting GalNAc-siRNA Conjugate.

  2017cites this paper
• Addressing Common Questions Encountered in the Diagnosis and Management of Cardiac Amyloidosis

  2017cites this paper
• Safety of antisense oligonucleotide and siRNA-based therapeutics.

  2017cites this paper
• Novel pharmacotherapies for cardiac amyloidosis

  2017cites this paper
• Brazilian consensus for diagnosis, management and treatment of transthyretin familial amyloid polyneuropathy

  2017cites this paper
• Towards targets and treatments in transthyretin amyloidosis

  2017cites this paper
• RNA Therapeutics in Oncology: Advances, Challenges, and Future Directions

  2017cites this paper
• Liver transplantation in transthyretin amyloidosis: Characteristics and management related to kidney disease.

  2017cites this paper
• Transthyretin V122I (pV142I)* cardiac amyloidosis: an age-dependent autosomal dominant cardiomyopathy too common to be overlooked as a cause of significant heart disease in elderly African Americans

  2017cites this paper
• Transthyretin and Retinol-Binding-Protein system: from functional and structural properties to pathological implications

  2017cites this paper
• Transthyretin-Related Familial Amyloid Polyneuropathy: In the Light of New Developments

  2017cites this paper
• In vitro modelling of familial amyloidotic polyneuropathy allows quantitative detection of transthyretin amyloid fibril-like structures in hepatic derivatives of patient-specific induced pluripotent stem cells

  2017cites this paper
• One mutation, two distinct disease variants: unravelling the impact of transthyretin amyloid fibril composition

  2017cites this paper
• Amyloid heart disease: genetics translated into disease-modifying therapy

  2017cites this paper
• Early skin denervation in hereditary and iatrogenic transthyretin amyloid neuropathy

  2017cites this paper
• Novel conformation-specific monoclonal antibodies against amyloidogenic forms of transthyretin

  2016cites this paper
• The notorious R.N.A. in the spotlight - drug or target for the treatment of disease

  2016cites this paper
• Drugs for the treatment of peripheral neuropathies

  2016cites this paper
• Constrictive Pericarditis Versus Restrictive Cardiomyopathy?

  2016cites this paper
• Carpal tunnel syndrome: a common initial symptom of systemic wild-type ATTR (ATTRwt) amyloidosis

  2016cites this paper
• Newer Therapies for Amyloid Cardiomyopathy

  2016cites this paper
• Modelling Amyloidosis in Mice

  2016cites this paper
• Comprehensive Structure-Activity Relationship of Triantennary N-Acetylgalactosamine Conjugated Antisense Oligonucleotides for Targeted Delivery to Hepatocytes.

  2016cites this paper
• Pilot study for left ventricular imaging phenotype of patients over 65 years old with heart failure and preserved ejection fraction: the high prevalence of amyloid cardiomyopathy

  2016cites this paper
• The Prevalence and Management of Systemic Amyloidosis in Western Countries

  2016cites this paper
• Neurologic Manifestations of Systemic Disease ( N Scolding and C Rice , Section Editors ) Current and Future Treatment Approaches in Transthyretin Familial Amyloid Polyneuropathy

  2016cites this paper
• Survival After Transplantation in Patients With Mutations Other Than Val30Met: Extracts From the FAP World Transplant Registry

  2016cites this paper
• Precision medicine, genomics and drug discovery.

  2016cites this paper
• Transthyretin Cardiac Amyloidosis in Older Americans.

  2016cites this paper
• Selection of transthyretin amyloid inhibitors

  2016cites this paper
• Oligonucleotide therapies for RNA and DNA : modulation of natural splice-variants, DNA structure & characterization of new synthetic nucleotides and reporter cell lines

  2016cites this paper
• TTR kinetic stabilizers and TTR gene silencing: a new era in therapy for familial amyloidotic polyneuropathies

  2016cites this paper
• Cardiac Dysautonomia Predicts Long-Term Survival in Hereditary Transthyretin Amyloidosis After Liver Transplantation.

  2016cites this paper
• Loss of Frataxin activates the iron/sphingolipid/PDK1/Mef2 pathway in mammals

  2016cites this paper
• Evaluation of Therapeutic Oligonucleotides for Familial Amyloid Polyneuropathy in Patient-Derived Hepatocyte-Like Cells

  2016cites this paper
• DNA and RNA derivatives to optimize distribution and delivery.

  2015cites this paper
• Infiltrative Cardiomyopathies

  2015cites this paper
• Emerging Advances in the Management of Cardiac Amyloidosis

  2015cites this paper
• Diagnosis, Prognosis, and Therapy of Transthyretin Amyloidosis.

  2015cites this paper
• Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction.

  2015cites this paper
• Tafamidis in transthyretin amyloid cardiomyopathy: effects on transthyretin stabilization and clinical outcomes.

  2015cites this paper
• Evolving landscape in the management of transthyretin amyloidosis

  2015cites this paper
• Bifunctional crosslinking ligands for transthyretin

  2015cites this paper
• Therapeutic Oligonucleotides Targeting Liver Disease: TTR Amyloidosis

  2015cites this paper
• Recent advances in familial amyloid polyneuropathy.

  2015cites this paper
• Emerging treatments for amyloidosis.

  2015cites this paper
• The transthyretin amyloidoses: advances in therapy

  2015cites this paper
• Natural history and therapy of TTR-cardiac amyloidosis: emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugs

  2015cites this paper
• Noncoding oligonucleotides: the belle of the ball in gene therapy.

  2015cites this paper
• Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments

  2015cites this paper
• Familial amyloidosis: great progress for an orphan disease.

  2015cites this paper
• Hepatic-Based Inborn Errors of Metabolism

  2015cites this paper
• Genotype–phenotype correlation and course of transthyretin familial amyloid polyneuropathies in France

  2015cites this paper
• Novel strategies for the diagnosis and treatment of cardiac amyloidosis

  2015cites this paper
• An evaluation of current treatment options for immunoglobulin light-chain amyloidosis

  2014cites this paper
• Familial amyloid polyneuropathy: elaboration of a therapeutic patient education programme, “EdAmyl”

  2014cites this paper
• Recent advances in transthyretin amyloidosis therapy

  2014cites this paper
• Transthyretin Antisense Oligonucleotides Lower Circulating RBP4 Levels and Improve Insulin Sensitivity in Obese Mice

  2014cites this paper
• In silico analysis of TTR gene (coding and non-coding regions, and interactive network) and its implications in transthyretin-related amyloidosis

  2014cites this paper
• Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction.

  2014cites this paper
• An overview of drugs currently under investigation for the treatment of transthyretin-related hereditary amyloidosis

  2014cites this paper
• Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice

  2014cites this paper